Skip to content
Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection? episode artwork

Jun 18, 2015 10 min

Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?

from GRACEcast Hosted by cancerGRACE Meetings

The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?

0:00 10:45

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of GRACEcast?

This episode is 10 minutes long.

When was this GRACEcast episode published?

This episode was published on June 18, 2015.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.